1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Cystic Fibrosis Partnering 2010-2015

Cystic Fibrosis Partnering 2010-2015

  • May 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

Summary
The Cystic Fibrosis Partnering 2010-2015 report provides understanding and access to the cystic fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Cystic Fibrosis Partnering 2010-2015 report provides understanding and access to the Cystic fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Cystic fibrosis partnering deals
Top Cystic fibrosis deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Cystic fibrosis Partnering 2010-2015 provides understanding and access to the Cystic fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of Cystic fibrosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Cystic fibrosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 60 links to online copies of actual Cystic fibrosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of Cystic fibrosis partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cystic fibrosis technologies and products.

Report scope

Cystic fibrosis Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to Cystic fibrosis trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in Cystic fibrosis dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 60 Cystic fibrosis deals
The leading Cystic fibrosis deals by value since 2010

In Cystic fibrosis Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Cystic Fibrosis Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of cystic fibrosis deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 60 actual cystic fibrosis deals entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Keywords

cystic fibrosis respiratory, partnering, licensing, deals, alliances, merger and acquisition, M&A, big pharma

Table Of Contents

Cystic Fibrosis Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cystic fibrosis partnering

2.1. Introduction
2.2. Cystic fibrosis partnering over the years
2.3. Cystic fibrosis partnering by deal type
2.4. Cystic fibrosis partnering industry sector
2.5. Cystic fibrosis partnering by stage of development
2.6. Cystic fibrosis partnering by technology type

Chapter 3 - Average deal terms for Cystic fibrosis

3.1 Introduction
3.2 Average deal terms for cystic fibrosis
3.3 Cystic fibrosis headline values with median calculation
3.4 Cystic fibrosis upfront values with median calculation
3.5 Cystic fibrosis milestone values with median calculation
3.6 Cystic fibrosis royalty rates with median calculation

Chapter 4 - Active Cystic fibrosis dealmakers

4.1. Introduction
4.2 Most active Cystic fibrosis dealmakers
4.3. Top Cystic fibrosis deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Cystic fibrosis dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Cystic fibrosis partnering since 2010
Figure 2: Cystic fibrosis dealmaking activity- 2010 to 2015
Figure 3: Cystic fibrosis partnering by deal type since 2010
Figure 4: Cystic fibrosis partnering by industry sector since 2010
Figure 5: Cystic fibrosis partnering by stage of development since 2010
Figure 6: Cystic fibrosis partnering by technology type since 2010
Figure 7: Cystic fibrosis deals with a headline value
Figure 8: Cystic fibrosis deals with upfront payment values
Figure 9: Cystic fibrosis deals with milestone payments
Figure 10: Cystic fibrosis deals with royalty rates, %
Figure 11: Top Cystic fibrosis deals by value since 2010
Figure 12: Big pharma - top 50 - Cystic fibrosis deals 2010 to 2015
Figure 13: Big pharma cystic fibrosis deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - Cystic fibrosis deals 2010 to 2015
Figure 15: Big biotech cystic fibrosis deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cystic fibrosis- Market Insights, Epidemiology and Market Forecast-2023

Cystic fibrosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Cystic fibrosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Cystic fibrosis - Epidemiology Forecast To 2023

Cystic fibrosis - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Cystic fibrosis - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Cystic fibrosis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). ...

Global Cystic Fibrosis Therapeutics Market 2016-2020

Global Cystic Fibrosis Therapeutics Market 2016-2020

  • $ 2500
  • Industry report
  • October 2016
  • by Infiniti Research Limited

About Cystic Fibrosis Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.